Biologics for Mastocytosis? New Evidence Supports Targeted Treatment Success
Could the next breakthrough for mastocytosis already be in your therapeutic toolbox?
A new article in the July issue of JDD maps the evolving treatment landscape of mastocytoses, covering cutaneous (CM), systemic (SM), and even rare mast cell sarcoma (MCS). As our understanding of mast cell biology grows, so does the promise of targeted therapies, especially biologics.
The study analyzed 55 papers and found that over 90% of patients treated with tyrosine kinase inhibitors (TKIs), including JAK1/2 inhibitors like ruxolitinib, showed symptom improvement or disease resolution. Monoclonal antibodies also yielded success in more than 90% of cases.
While clinical trial data, particularly on JAK inhibitors, are still limited, these findings highlight a crucial shift: mastocytosis may no longer be a therapeutic gray zone. With more biologic agents on the radar, dermatologists managing CM or referring SM cases should keep these options top-of-mind.
Are you up to date on the biologics that could change the course of mastocytosis care?
J Drugs Dermatol. 2025;24(7). doi:10.36849/JDD.8437R1
